We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: obesity
MedXY News
EnglishTag

obesity

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity
newsactive surveillancemetformin

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity

By MedXY|Nov 23, 2025

A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.

Adenotonsillectomy Lowers Blood Pressure Percentiles in Children With Mild OSA — Greatest Benefit in Overweight Kids
Cardiologyadenotonsillectomyblood pressure

Adenotonsillectomy Lowers Blood Pressure Percentiles in Children With Mild OSA — Greatest Benefit in Overweight Kids

By MedXY|Nov 20, 2025

An exploratory analysis of the PATS randomized trial found early adenotonsillectomy reduced 12‑month systolic and diastolic BP percentiles versus watchful waiting in children with mild obstructive sleep‑disordered breathing, with larger DBP

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS
Diabetes & EndocrinologyobesityPCOS

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

By MedXY|Nov 13, 2025

A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promisi

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit
Cardiologycardiovascular outcomesobesity

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

By MedXY|Nov 11, 2025

In the SELECT trial, weekly semaglutide 2.4 mg reduced major adverse cardiovascular events in people with overweight/obesity without diabetes. Benefits were largely independent of baseline adiposity and weight loss; waist circumference redu

Trunk Inclination Changes Worsen Compliance and Raise PaCO2 in Obese ARDS Patients: Clinical Implications from a Seven-Study Pooled Analysis
Critical CareARDSmechanical ventilation

Trunk Inclination Changes Worsen Compliance and Raise PaCO2 in Obese ARDS Patients: Clinical Implications from a Seven-Study Pooled Analysis

By MedXY|Nov 7, 2025

A secondary analysis of 159 mechanically ventilated ARDS patients shows that increasing trunk inclination reduces respiratory system, lung, and chest wall compliance—especially in patients with obesity—and is associated with increased PaCO2

Microbiota, 3‑Hydroxyanthranilic Acid and Dopaminergic Signalling: A New Pathway Linking Obesity to Attention Deficits
Gastroenterologymicrobiomeobesity

Microbiota, 3‑Hydroxyanthranilic Acid and Dopaminergic Signalling: A New Pathway Linking Obesity to Attention Deficits

By MedXY|Nov 7, 2025

A multi-cohort human study with mouse and Drosophila validation implicates gut microbes and the tryptophan metabolite 3‑hydroxyanthranilic acid in modulating attention in obesity, suggesting microbiota-directed interventions could improve c

Obesity Alters Symptom Trajectory and Inflammatory Signatures after Sport-Related Concussion: the NCAA‑DoD CARE Consortium
Diabetes & Endocrinologybiomarkersinflammation

Obesity Alters Symptom Trajectory and Inflammatory Signatures after Sport-Related Concussion: the NCAA‑DoD CARE Consortium

By MedXY|Nov 4, 2025

In a large prospective cohort, obese BMI (≥30) was associated with worse post-concussion neurocognitive outcomes and a persistently proinflammatory blood biomarker profile, despite fewer baseline symptoms. Findings suggest obesity modifies

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence
Diabetes & EndocrinologyGLP-1 receptor agonistsliraglutide

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

By MedXY|Oct 31, 2025

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, ad

Disentangling Clinical and Preclinical Obesity: Their Distinct Impacts on All-Cause Mortality Risk in the UK Biobank Study
Diabetes & Endocrinologyclinical obesitymortality risk

Disentangling Clinical and Preclinical Obesity: Their Distinct Impacts on All-Cause Mortality Risk in the UK Biobank Study

By MedXY|Oct 29, 2025

New evidence from the UK Biobank reveals that clinical obesity, defined by obesity-related dysfunctions, significantly elevates all-cause mortality risk. Early detection and intervention are key to reducing mortality associated with both pr

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review
Diabetes & Endocrinologyliver functionMASLD

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

By MedXY|Oct 28, 2025

This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver healt

Simultaneous Liver Transplant and Sleeve Gastrectomy: A Dual Approach to Combat Obesity and MASLD with Durable Outcomes
Gastroenterologybariatric surgeryliver transplant

Simultaneous Liver Transplant and Sleeve Gastrectomy: A Dual Approach to Combat Obesity and MASLD with Durable Outcomes

By MedXY|Oct 27, 2025

Combining liver transplant with sleeve gastrectomy yields sustained weight loss, improved metabolic syndrome, and reduced liver allograft steatosis, without increasing mortality or graft loss, offering an effective treatment for obese patie

Bariatric Surgery Significantly Reduces Risk of Developing Major Obesity-Related Comorbidities: Insights from a Large Veterans Cohort
Diabetes & Endocrinologybariatric surgeryHypertension

Bariatric Surgery Significantly Reduces Risk of Developing Major Obesity-Related Comorbidities: Insights from a Large Veterans Cohort

By MedXY|Oct 27, 2025

A large retrospective cohort study reveals bariatric surgery markedly lowers the incidence of key metabolic comorbidities compared to weight management alone in obese veterans, supporting its role in durable obesity-related risk reduction.

Comparative Effectiveness and Costs of Bariatric Surgery Versus GLP-1 Receptor Agonists in Obesity Management
Internal Medicinebariatric surgeryGLP-1 receptor agonists

Comparative Effectiveness and Costs of Bariatric Surgery Versus GLP-1 Receptor Agonists in Obesity Management

By MedXY|Oct 27, 2025

This article reviews recent evidence comparing weight loss outcomes and healthcare costs of bariatric surgery and GLP-1 receptor agonists, highlighting implications for clinical decision-making in treating class II and III obesity.

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults
Diabetes & Endocrinologyage-related macular degenerationGLP-1 receptor agonists

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

By MedXY|Oct 25, 2025

A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudat

Integrating Obesity Management into Cardiac Rehabilitation: Challenges, Evidence, and Future Directions
Cardiologycardiovascular healthobesity

Integrating Obesity Management into Cardiac Rehabilitation: Challenges, Evidence, and Future Directions

By MedXY|Oct 24, 2025

Obesity management in cardiac rehabilitation (CR) is underutilized despite its cardiovascular benefits. This review explores the evidence, complexities, patient perspectives, and healthcare provider attitudes, emphasizing tailored strategie

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT
Diabetes & Endocrinologyobesityprediabetes

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

By MedXY|Oct 22, 2025

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychi

Revisiting Obesity Classification: Insights from a Population-Based Survey in Peru Using New Clinical Frameworks
Diabetes & EndocrinologyBMIclinical obesity

Revisiting Obesity Classification: Insights from a Population-Based Survey in Peru Using New Clinical Frameworks

By MedXY|Oct 19, 2025

This review examines a landmark Peruvian study applying new obesity definitions that incorporate clinical dysfunction and adiposity measures beyond BMI, revealing substantial underdiagnosis with traditional approaches and ethnic variation i

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial
Diabetes & Endocrinologyclinical trialobesity

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

By MedXY|Oct 18, 2025

The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review
Diabetes & Endocrinologyclinical trialmetabolic syndrome

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

By MedXY|Oct 18, 2025

This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health
Diabetes & Endocrinologylifestyle interventionsmale fertility

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health

By MedXY|Oct 12, 2025

This systematic review and meta-analysis evaluates the effects of obesity interventions—lifestyle modification, pharmacotherapy, and bariatric surgery—on male fertility, highlighting improvements with lifestyle changes and limited benefits

Prev
4 / 7
1234567
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities